111 related articles for article (PubMed ID: 5675486)
1. Effect of phenothiazines on dopamine metabolism and biochemistry of Parkinson's disease.
Barbeau A
Agressologie; 1968; 9(2):195-200. PubMed ID: 5675486
[No Abstract] [Full Text] [Related]
2. [l-dopa treatment of Parkinson's syndrome and mechanism of action of neuroleptics].
Degkwitz R
Med Klin; 1969 Aug; 64(33):1451-6. PubMed ID: 4896563
[No Abstract] [Full Text] [Related]
3. [Drug-induced Parkinson's syndrome].
Degkwitz R
Dtsch Med Wochenschr; 1972 Jun; 97(22):882. PubMed ID: 5032182
[No Abstract] [Full Text] [Related]
4. [Disturbances of catecholamine metabolism (with special reference to dopamine) in the Parkinsonian syndrome].
Tissot R
Presse Med (1893); 1969 Apr; 77(17):617-8. PubMed ID: 5785080
[No Abstract] [Full Text] [Related]
5. [Drug-induced Parkinson's syndrome with cycle-dependent hyperkineses following intake of the contraceptive "Gestakliman"].
Jörg J
Nervenarzt; 1971 Jun; 42(6):325-9. PubMed ID: 4397217
[No Abstract] [Full Text] [Related]
6. [Biochemistry and treatment of Parkinson's disease].
Barbeau A
Laval Med; 1970 Sep; 41(7):902-5. PubMed ID: 5509487
[No Abstract] [Full Text] [Related]
7. [Influencing of Parkinson's syndrome via intervention in the dopamine metabolism].
Korten JJ; van Rossum JM
Ned Tijdschr Geneeskd; 1973 Feb; 117(8):296-305. PubMed ID: 4350090
[No Abstract] [Full Text] [Related]
8. Recent advances in Parkinson's disease.
Vécsei L
Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
[No Abstract] [Full Text] [Related]
9. Dopaminergic regulation of cholinergic neurons in the striatum: relation to Parkinsonism.
Bartholini G; Lloyd KG; Stadler H
Adv Neurol; 1974; 5():11-4. PubMed ID: 4440567
[No Abstract] [Full Text] [Related]
10. Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease.
Elsworth JD; Roth RH
Exp Neurol; 1997 Mar; 144(1):4-9. PubMed ID: 9126143
[TBL] [Abstract][Full Text] [Related]
11. A dopaminergic-cholinergic mechanism in production of psychotic symptoms.
Friedhoff AJ; Alpert M
Biol Psychiatry; 1973 Apr; 6(2):165-9. PubMed ID: 4709131
[No Abstract] [Full Text] [Related]
12. [Striatal dopamine availability in Parkinson's disease--with reference to the wearing-off phenomenon].
Indo T
Rinsho Shinkeigaku; 1984 Oct; 24(10):1008-16. PubMed ID: 6518691
[No Abstract] [Full Text] [Related]
13. Medications for Parkinson's disease.
Whitney CM
Neurologist; 2007 Nov; 13(6):387-8. PubMed ID: 18090719
[No Abstract] [Full Text] [Related]
14. Parkinson's disease. Dopamine may sustain toxic protein.
Couzin J
Science; 2001 Nov; 294(5545):1257-8. PubMed ID: 11701896
[No Abstract] [Full Text] [Related]
15. [Updates in practical neurology--I. The principles of modern levodopa therapy in Parkinson's disease].
Klivényi P; Vécsei L
Ideggyogy Sz; 2007 Jan; 60(1-2):61-4. PubMed ID: 17432097
[TBL] [Abstract][Full Text] [Related]
16. What has been learnt from study of dopamine receptors in Parkinson's disease?
Hurley MJ; Jenner P
Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
[TBL] [Abstract][Full Text] [Related]
17. [The drug-induced Parkinson's syndrome].
Pakesch E
Wien Z Nervenheilkd Grenzgeb; 1966; 23(1):140-6. PubMed ID: 4226879
[No Abstract] [Full Text] [Related]
18. CDKs: taking on a role as mediators of dopaminergic loss in Parkinson's disease.
Smith PD; O'Hare MJ; Park DS
Trends Mol Med; 2004 Sep; 10(9):445-51. PubMed ID: 15350897
[No Abstract] [Full Text] [Related]
19. Dopamine agonists and Parkinson's disease progression: what can we learn from neuroimaging studies.
Marek K; Jennings D; Seibyl J
Ann Neurol; 2003; 53 Suppl 3():S160-6; discussion S166-9. PubMed ID: 12666107
[No Abstract] [Full Text] [Related]
20. Functional integration of neural grafts in Parkinson's disease.
Barker RA; Dunnett SB
Nat Neurosci; 1999 Dec; 2(12):1047-8. PubMed ID: 10570477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
